GLYCART’s mission is to become an antibody powerhouse within the Roche Group developing a new generation of antibody products with increased efficacy that address unmet clinical needs.

GLYCART’s core platform technology – GlycoMAb® – enhances the power of monoclonal antibodies.

GLYCART was acquired by Roche

On July 19, 2005, Roche announced that it has acquired GLYCART to strengthen its expertise in therapeutic antibody research. The acquisition was completed on July 26, 2005. For further information about Roche, please visit or click on the logo below to be connected to the Roche webpage.